Effects of YM358,an Angiotensin II Type 1 (AT_1) Receptor Antagonist, and Enalapril on Blood Pressure and Vasoconstriction in Two Renal Hypertension Models

スポンサーリンク

概要

• 論文の詳細を見る

• The effects of the angiotensin II type 1 receptor antagonist YM358 on blood pressure were compared to those of the angiotensin converting enzyme inhibitor enalapril in one-kidney, one-clip renal hypertensive rats(1K1C RHR), two-kidney, one-clip renal hypertensive rats (2K1C RHR) and normotensive rats (NTR). Additionally, the local drug actions in peripheral tissues were investigated using isolated mesenteric arteries from these rats. In 2K1C RHR, YM358 and enalapril produced a long-lasting hypotensive effect in a dose-dependent manner. In 1K1C RHR, YM358 (30 mg/kg) also produced an antihypertensive effect, whereas enalapril (30 mg/kg)had no effect. Administration of YM358,but not enalapril, to 1K1C RHR, 2K1C RHR and NTR did not affect heart rate. In isolated mesenteric arteries from 1K1C RHR and 2K1C RHR, angiotensin II (Ang II), angiotensin I (Ang I) and tetradecapeptide (TDP), a physiologically active renin substrate, produced concentration-dependent vasoconstriction. YM358 (10^<-7> M) inhibited the vasoconstricting responses to Ang II, Ang I and TDP in isolated mesenteric arteries. In contrast, enalaprilat (10^<-7>M), an active metabolite of enalapril, did not completely inhibit the response to Ang I and TDP. These results indicate that YM358 has higher efficary than enalapril for the treatment of hypertension.

• 公益社団法人日本薬学会の論文
• 2000-02-01

著者

• FUJIMORI Akira

  Applied Pharmacology Research Laboratories, Drug Discovery Research, Astellas Pharma Inc.

• UCHIDA Wataru

  Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd.

• Matsuda-satoh Yasuko

  Institute For Drug Discovery Research Yamanouchi Pharmaceutical Co.

• Uchida W

  Yamanouchi Pharmaceutical Co. Ltd. Ibaraki Jpn

• Uchida Wataru

  Institute For Drug Discovery Research Yamanouchi Pharmaceutical Co. Ltd.

• Fujimori Akira

  アステラス製薬研究本部薬理研究所

• Fujimori Akira

  Applied Pharmacology Research Laboratories Drug Discovery Research Astellas Pharma Inc.

• Yanagisawa I

  Yamanouchi Pharmaceutical Co. Ltd. Ibaraki Jpn

• Yanagisawa Isao

  Institute For Drug Discovery Research Yamanouchi Pharmaceutical Co.

• Yanagisawa Isao

  山之内製薬

• Fujimori Akira

  Institute For Drug Discovery Research Yamanouchi Pharmaceutical Co. Ltd.

• Shibasaki Masayuki

  Institute For Drug Discovery Research Yamanouchi Pharmaceutical Co.

• Shibasaki Masayuki

  General Education Courses Faculty Of Engineering Toyo University

• Inagaki Osamu

  Institute For Drug Discovery Research Yamanouchi Pharmaceutical Co.

• Fujimori Akira

  Institute For Drug Discovery Research Yamanouchi Pharmaceutical Co.

• TOKIOKA Tomoko

  (Present address)Clinical Development Coordination Department, Yamanouchi Pharmaceutical Co., Ltd.,

• TOKIOKA-AKAGI Tomoko

  Biometrics Department, Yamanouchi Pharmaceutical Co., Ltd.

• Tokioka-akagi Tomoko

  Biometrics Department Yamanouchi Pharmaceutical Co. Ltd.

関連論文

• New Topics in Vasopressin Receptors and Approach to Novel Drugs : Research and Development of Conivaptan Hydrochloride (YM087), a Drug for the Treatment of Hyponatremia
• Characterization of the Pharmacology of YM-198313 on Volume-Regulated Anion Channels(Pharmacology)
• Synthesis and Structure-Activity Relationships in a Series of Ethenesulfonamide Derivatives, a Novel Class of Endothelin Receptor Antagonists
• Ethenesulfonamide Derivatives, a Novel Class of Orally Active Endothelin-A Receptor Antagonists
• Novel Potassium Channel Activators : Synthesis and Structure-Activity Relationship Studies of 3,4-Dihydro-2H-1,4-benzoxazine Derivatives
• An Easy Access to 7-Methyl-2-naphthalenecarbonitrile
• Studies on Nonpeptide Angiotensin II Receptor Antagonists. IV. Synthesis and Biological Evaluation of 4-Acrylamide-1H-imidazole Derivatives
• Studies on Nonpeptide Angiotensin II Receptor Antagonists. III. Synthesis and Biological Evaluation of 5-Alkylidene-3,5-dihydro-4H-imidazol-4-one-Derivatives
• Studies on Nonpeptide Angiotensin II Receptor Antagonists. II. Synthesis and Biological Evaluation of 5H-Pyrazolo[1,5-b][1,2,4]triazole Derivatives with a C-Linked Oxygen Functional Group at the 6-Position
• Studies no Nonpeptide Angiotensin II Receptor Antagonists. I. Synthesis and Biological Evaluation of Pyrazolo[1,5-b][1,2,4]triazole Derivatives with Alkyl Substituents
• Novel Potassium Chennel Activators. II. Synthesis and Pharmacological Evaluation of 3,4-Dihydro-2H-1,4-benzoxazine Derivatives : Modificaiton of the Aromatic Part
• Cardiovascular Effects of YM430,a 1,4-Dihydropyridine Derivative with β-Adrenoceptor Blocking Activity, in Dogs and Rats
• Synthesis and Biological Evaluation of Quinuclidine Derivatives Incorporating Phenothiazine Moieties as Squalene Synthase Inhibitors
• Comparison between YM099 and Captopril in Rats with Renal Mass Reduction-Induced Progressive Renal Disease(Pharmacology)
• Novel Potassium Channel Activators. III. Synthesis and Pharmacological Evaluation of 3,4-Dihydro-2H-1,4-benzoxazine Derivatives : Modification at the 2 Position
• Hypotensive Effects of YM430, a 1 ,4 : Dihydropyridine Derivative, in Spontaneously Hypertensive Rats and Renal Hypertensive Dogs
• Synthesis of Novel Succinamide Derivatives Having the 5,11-Dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one Skeleton as Potent and Selective M_2 Muscarinic Receptor Antagonists. I
• Novel 5-Hydroxytryptamine (5-HT_3) Receptor Antagonists. Synthesis and Structure-Activity Relationships of 9-Methyl-2,3,4,9-tetrahydrothiopyrano[2,3-b]indol-4-one Derivatives
• Novel 5-Hydroxytryptamine (5-HT_3) Receptor Antagonists. III. Pharmacological Evaluations and Molecular Modeling Studies of Optically Active 4,5,6,7-Tetrahydro-1H-benzimidazole Derivatives
• Novel 5-Hydroxytryptamine (5-HT_3) Receptor Antagonists. II. Synthesis and Structure-Activity Relationships of 4,5,6,7-Tetrahydro-1H-benzimidazole Derivatives
• Novel 5-Hydroxytryptamine (5-HT_3) Receptor Antagonists. I. Synthesis and Structure-Activity Relationships of Conformationally Restricted Fused Imidazole Derivatives
• Antisecretory and Antiulcer Effects of YM020, a New H^+, K^+-ATPase Inhibitor, in Rats and Dogs
• A Novel Vasopressin Dual V_/V_2 Receptor Antagonist, Conivaptan Hydrochloride, Improves Hyponatremia in Rats with Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH)(Pharmacology)
• Synthesis and Pharmacological Evaluation of 2-(3-Piperidyl)-1,2,3,4-tetrahydroisoquinoline Derivatives as Specific Bradycardic Agents
• Synthesis and Biological Evaluation of Phenylacetyl Derivatives Having Low Central Nervous System Permeability as Potent and Selective M_2 Muscarinic Receptor Antagonists
• Synthesis of Novel Succinamide Derivatives Having a 5,11-Dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one Skeleton as Potent and Selective M_2 Muscarinic Receptor Antagonists. II
• Effects of YM358,an Angiotensin II Type 1 (AT_1) Receptor Antagonist, and Enalapril on Blood Pressure and Vasoconstriction in Two Renal Hypertension Models
• In Vitro and in Vivo Vasodilatory Activity of barnidipine and Its Enantiomers
• Effects of Angiotensin II Type 1 Receptor Antagonist, YM358, on Cardiac Hypertrophy and Dysfunction after Myocardial Infarction in Rats
• Comparison of the Angiotensin II Type 1-Receptor Antagonist YM358 and the Angiotensin-Converting Enzyme Inhibitor Enalapril in Rats With Cardiac Volume Overload
• Nuclear Magnetic Resonance of ^7Li in Li_2B_4O_7 Single Crystal and Glass
• Nuclear Magnetic Resonance of ^7Li in LiBO_2 Crystal
• Antihypertensive Effect of YM730, A New Calcium Antagonist, in Stroke-prone Spontaneously Hypertensive Rats

もっと見る 閉じる

スポンサーリンク